J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences
Headline as filed by CNBC Top News.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| CNBC Top News | J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences |
Johnson & Johnson will acquire Ollin for $2.2 billion upfront, with the potential for milestone payments of up to about $1.13 billion, the drugmaker said. |
0m | cnbc.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.